top of page

December 1, 2020 through April 30, 2021

Oura Ring 05.jpg


The TemPredict Study began on December 1st, 2020, and has two phases.  

  • In Phase 1, researchers will assess whether information from a device worn on any finger (Oura Ring), like body temperature, can help identify early COVID- 19 disease. 

  • In Phase 2, researchers plan to use what they learn in the first phase to tell participants if information from the Oura Ring suggests they should get testing for COVID-19. The second phase will only happen if the first phase suggests that the Oura Ring is useful in identifying if someone might have early COVID-19 disease or other viral infections.  

Why is this study being done?  

  • The purpose of this study is to test whether information such as body temperature, heart rate, and respiratory rate, collected from a device worn on any finger (Oura ring), can identify if someone might have early COVID-19 or possibly influenza. Researchers will combine information to create a measure (algorithm) that estimates the chance of someone having COVID-19 or influenza.  

  • In Phase 1, researchers will collect information from the device and questionnaires from participants. Researchers will use both types of data to develop an algorithm to identify early COVID-19 or influenza. Phase 1 is similar to the TemPredict study that you have participated in. The primary difference is that you will get a link in a text message each morning to questions about your symptoms, instead of a link to the daily symptom questions through the Oura App.  

  • In Phase 2, researchers aim to test whether the algorithm actually works the way they expect. They will test if the algorithm correctly identifies participants with early COVID-19 or influenza. If the algorithm indicates that someone may have signs of early COVID-19 or influenza, study staff will contact the participant to let them know. Staff will suggest getting COVID-19 or influenza testing if indicated. The study will provide information about how to participants can get these tests. The study will cover costs of these tests.  


What does participation in Phase 1 involve?  

  • Complete a brief consent survey online. This takes 3-5 minutes. 

  • Digitally sign a consent form in Docusign. 

  • Complete COVID-19 antibody testing at a LabCorp location convenient for you. 

  • Complete a baseline survey. This takes about 20 minutes.   

  • Wear an Oura Ring while you sleep until April 30th, 2021.  

  • Allow study researchers to access your Oura Ring data. 

  • Receive daily text messages through which to report any COVID-19 symptoms. This takes about 20 seconds. 

  • Complete monthly questionnaires about your health and exposure to COVID-19. These take about 5 minutes.  


What does participation in Phase 2 involve?  

  • Continue participating as in Phase 1  

  • Complete COVID-19 antibody testing at a LabCorp location convenient for you at the end of Phase 2 

  • Receive (by mail) an Everlywell self-collection (nasal swab collected just inside the nose) kit for collecting a COVID-19 and possibly also influenza test specimen at home.  

  • Complete an Everlywell at-home COVID-19 (and possibly also influenza) test if researchers instruct you to do so. Researchers will contact you by text message or telephone to ask you to complete this test. You can access results using your own account login about 24-72 hours after Everlywell receives your completed kit.  

  • If you have other access to COVID-19 and/or influenza testing, such as from your doctors, or at a health center or other test site, you can choose to do this in addition to having testing done by TemPredict researchers. The study will not be able to pay for testing you have done with your doctors or at a health center. The testing provided by the study is free of charge.  

  • Receive a meta-genomic testing kit if you consented to receive one. Only about 200 participants will receive these additional nasal swab kits. Researchers will use this additional swab kit to test for other possible respiratory infections, not just COVID-19 or influenza. Meta-genomic sequencing can detect viral genetic sequences from many different viruses. Results will not be available until later in the study because the tests need to be run in a single batch.  

  • You may receive an invitation to extend your participation in this study beyond April 30, 2021.  

  • You will be able to keep the Oura Ring that the study provided to you if you complete the study through April 30th, 2021. This means completing both blood draws for COVID-19 antibody testing and, if study staff contact you to, providing a nasal swab to the researchers using a pre- paid mailer. It also means wearing the Oura ring nightly during the study and responding to most of the daily surveys. If you choose to stop participating in the study, we will provide you with a pre-paid shipping label with which to return the Oura ring the TemPredict study provided you. 

Study location

  • All study components will be done over the internet, by mail, or at a LabCorp location of your choice. 

Questions? You can learn more:  

bottom of page